1617 - BRAF V600 mutation testing to determine eligibility for PBS access to Braftovi (encorafenib) in patients with metastatic colorectal cancer

Page last updated: 12 February 2020

Application Detail

Description of Medical Service

The MBS item 73338 tests tumour tissue from a patient with metastatic colorectal cancer (stage IV) to determine if the requirements relating to rat sarcoma oncogene (RAS) gene mutation status for access to certain Pharmaceutical Benefits Scheme (PBS) medicines are fulfilled. This application seeks to amend item 73338 to include testing for BRAF V600 mutation status to determine eligibility for PBS access to encorafenib for metastatic colorectal cancer.

Reason for Application

Amendment to MBS item

Medical Service Type

Co-dependent technology

Previous Application Number/s

Not Applicable

Associated Documentation

Application Form

Application Form (PDF 1197 KB)
Application Form (Word 212 KB)

Consultation Survey

Consultation Survey (PDF 561 KB)
Consultation Survey (Word 70 KB)

PICO Confirmation

-

Assessment Report

-

Public Summary Document

-

Meetings for this Application

PASC

16-17 April 2020

ESC

-

MSAC

-